IRVING, Texas and PHOENIX, May 27, 2009 (GLOBE NEWSWIRE) -- Caris Diagnostics (Caris Dx) -- a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology -- today announced the appointment of a nationally-renowned oncologist, David Loesch, MD, as Director of Oncology, Clinical Trials and Services.
"Dr. Loesch has been a recognized leader in the oncology community for years, with a firm commitment to personalized care and oncology research. He will be instrumental to our goal of becoming the trusted provider of molecular profiling for cancer patients," says David D. Halbert, Chairman and CEO of Caris Dx. "The appointment of Dr. Loesch provides further evidence of our organizational commitment to the oncology market, as Caris Dx begins to define the future of individualized oncology care."
Loesch is widely recognized as one of the nation's foremost authorities on breast cancer diagnosis, treatment and research. He has served as Co-Chairman of the Breast Cancer Committee for the US Oncology (USO) Network and has been a practicing medical oncologist for over 18 years. In 2006, he was bestowed the Indiana Breast Cancer Alliance (IBCA) Medical Researcher "Excellence" Award and in 2007 was named the Indiana Breast Cancer Researcher of the Year by the Indiana Breast Cancer Coalition.
"This is an exciting time for Caris Dx, my clinical colleagues, and myself, as the field of clinical oncology rapidly shifts towards the molecular paradigm," Loesch says. "I look forward to helping Caris Dx develop our next generation Target Now(r) oncology testing service and strategically position ourselves to build one of the most robust and integrated molecular testing programs in the nation."
About Caris Diagnostics
Caris Dx is a U.S. based biosciences company specializing in development and commercialization of clinically-validated molecular diagnostics and anatomic pathology services primarily in the fields of oncology, dermatopathology, hematopathology and gastrointestinal pathology. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowships and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Dx also offers advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to assist physicians in their treatment of cancer and other complex diseases. Currently, Caris Dx receives and analyzes biopsies for more than 2,700 patients per day, referred by more than 2,500 physicians nationally. Formed in 1996, the company is headquartered in Irving, Texas and operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites) and Newton, Massachusetts. Additional information is available at www.carisdx.com.